Key result
SGLT2 inhibitors shorten QTc interval by ~17 ms vs. controls, improving ventricular repolarization homogeneity.
Why the study?
SGLT2 inhibitors reduce sudden cardiac death and ventricular arrhythmias in cardiovascular outcome trials, but the electrophysiological mechanism remains unclear.
Do SGLT2 inhibitors improve electrocardiographic markers of ventricular repolarization in patients with cardiometabolic disease?
Meta-Analysis (n=5,022)
Do SGLT2 inhibitors improve electrocardiographic markers of ventricular repolarization in patients with cardiometabolic disease?
Answers are grounded in this paper and cite their sources.
SGLT2 inhibitors favorably modify ECG markers of ventricular repolarization, providing a potential electrophysiological mechanism for their observed benefits in reducing sudden cardiac death and ventricular arrhythmias.
Background Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce sudden cardiac death and ventricular arrhythmias in cardiovascular outcome trials, but the electrophysiological mechanism remains unclear. Surface electrocardiographic (ECG) markers of repolarization dispersion may reflect myocardial electrical stability and provide mechanistic insight. Aim To assess the impact of SGLT2 inhibitors on electrocardiographic markers of ventricular repolarization dispersion and conduction, and to evaluate whether these changes are consistent with improved ventricular electrical stability. Methods We conducted a systematic review and meta-analysis of studies reporting ECG parameters before and after SGLT2 inhibitors and studies comparing SGLT2 inhibitors with other treatments. Searches were performed from database inception through June 2025 across Scopus, Web of Science, PubMed, Scilit, and Google Scholar. Random-effects inverse-variance models using restricted maximum likelihood with Hartung–Knapp adjustment were applied. Prespecified subgroup analyses were performed by follow-up duration. Results Seventeen studies involving 5022 patients were included. In pre–post analyses, SGLT2 inhibitors significantly reduced QTc (MD −4.9 ms), Tp-e (MD −6.12 ms), P dispersion (MD −3.28 ms), and QTc dispersion (MD −1.36 ms), while R–R interval, PR interval, and QRS duration remained unchanged. Improvements in Tp-e-related indices and QRS–T angle were more pronounced at 6 months. In two-arm comparisons, SGLT2 inhibitors significantly shortened QT interval, QTc, Tp-e, Tp-e/QT, and Tp-e/QTc compared with controls. Conclusion SGLT2 inhibitors reduce ECG markers of ventricular repolarization dispersion without affecting heart rate or conduction intervals, indicating improved ventricular electrical homogeneity.
No takes yet. Share an insight, caveat, or question.
Karsa et al. (2026) conducted a meta-analysis in Cardiometabolic disease (cardiovascular disease, diabetes mellitus, or heart failure) (n=5,022). SGLT2 inhibitors vs. Placebo, active comparators, or pre-treatment baseline was evaluated on QTc interval (two-arm comparison) (MD -17.46, 95% CI -29.15 to -5.77, p=0.009). SGLT2 inhibitors reduced QTc interval compared to control therapies, indicating improved ventricular electrical homogeneity.
Synapse has enriched 10 related papers. Consider them for comparative context: